Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Impact of Gum Infection on Heart Disease

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2011 by Boston University.
Recruitment status was  Active, not recruiting
Sponsor:
Collaborator:
Information provided by:
Boston University
ClinicalTrials.gov Identifier:
NCT00093236
First received: October 5, 2004
Last updated: March 29, 2011
Last verified: March 2011

October 5, 2004
March 29, 2011
September 2004
November 2010   (final data collection date for primary outcome measure)
Periodontal disease contributes to cardiovascular disease risk in human subjects and may lead to new approaches to therapy. [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
Periodontal disease contributes to cardiovascular disease risk in human subjects and may lead to new approaches to therapy.
Complete list of historical versions of study NCT00093236 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Impact of Gum Infection on Heart Disease
Systemic Endothelial Consequences of Periodontal Disease

The purpose of this study is to determine the effect of gum infection on parameters of cardio-vascular disease.

Epidemiological studies indicate that individuals with severe periodontal disease have significantly increased risk for cardiovascular disease. Periodontal disease, a chronic bacterial infection of the gums, is associated with recurrent bacteremia and a state of systemic inflammation that may convert endothelial cells to a pro-atherogenic phenotype with increased expression of inflammatory factors and loss of the anti-thrombotic, growth inhibitory, and vasodilator properties of the endothelium, including a decrease in the biological activity of nitric oxide. In human subjects, endothelial dysfunction has evolved into a well-accepted indicator of early atherosclerosis and predictor of increased cardiovascular disease risk. We have recently demonstrated a strong association between severe periodontal disease and endothelial vasomotor dysfunction in a case control study of otherwise healthy human subjects. In that study, periodontal disease was also associated with higher plasma levels of the acute phase reactant C-reactive protein (CRP). These results support the hypothesis that severe periodontal disease induces a state of systemic inflammation that impairs endothelial function, however, the cross-sectional design leaves open the possibility that confounding factors explain the results. We now propose to determine whether effective treatment of periodontal disease improves endothelial function (Aim 1) and reduces inflammation (Aim 2) in a randomized intervention study. Patients will receive comprehensive periodontal treatment designed to produce a state of periodontal health (scaling and root planing and periodontal surgery with re-treatment as needed) or routine oral hygiene and will be followed for 24 weeks. The study will examine endothelium-dependent brachial artery flow-mediated dilation, systemic markers of inflammation and endothelial activation (CRP, IL-6, myeloperoxidase, and ICAM-1), and oral markers of periodontitis (PGE2, myeloperoxidase, and pathogen DNA) before and after treatment. Compared to oral hygiene (which will stabilize, but not reverse periodontal disease), we hypothesize that comprehensive treatment of periodontal disease will improve endothelium-dependent dilation and reduce local and systemic inflammation. Further, we suggest that the degree of improvement in endothelial function will relate to the degree of reduction in specific markers of inflammation. Such results would provide much stronger evidence for causal links between periodontal disease, systemic inflammation, and endothelial dysfunction, a recognized surrogate for cardiovascular risk. The proposed studies will provide new insights into how periodontal disease contributes to cardiovascular disease risk in human subjects and may lead to new approaches to therapy.

Interventional
Phase 2
Phase 3
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Factorial Assignment
Masking: Single Blind (Investigator)
Primary Purpose: Treatment
  • Cardiovascular Disease
  • Periodontal Disease
Procedure: Periodontal therapy
comprehensive periodontal treatment
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
160
April 2011
November 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. The study seeks to enroll patients with periodontal disease and no other major co-morbidities including cardiovascular disease or other major medical problems.
  2. In this intervention study, cigarette smokers will be permitted as justified below and randomized in stratified fashion to ensure equal numbers in the two treatment groups.

Exclusion Criteria:

  1. Known cardiovascular disease including coronary heart disease, cerebral vascular disease, peripheral vascular disease, valvular heart disease, and congestive heart failure.
  2. Major coronary risk factors including diabetes mellitus, hypertension, hypercholesterolemia requiring treatment according to the ATP-III guidelines.
  3. Other major illness including cancer, liver disease, renal disease, pulmonary disease, chronic infectious disease (including HIV and hepatitis C infection), rheumatological disease, hematological disease, or any condition requiring hospitalization or chronic medical therapy.
  4. Use of antibiotics within three months.
  5. Use of oral contraceptives or hormone replacement therapy.
  6. Major psychiatric illness requiring treatment or that might interfere with the ability to understand and cooperate with the protocol.
  7. Ongoing drug or alcohol abuse.
  8. Use of sildenafil (Viagra) within 7 days because of the risk of marked hypotension with nitroglycerin administration.
  9. History of migraine headaches that might be exacerbated by nitroglycerin.
  10. Use of cholesterol lowering therapy, angiotensin converting enzyme inhibitors (subjects should not be taking these drugs because they will have no history of cardiovascular disease risk factors).
  11. Antioxidant vitamins (vitamin C or vitamin E) in doses exceeding the Recommended Dietary Allowances (RDA), (60 mg/day and 30 IU/day, respectively).
  12. Pregnancy, as diagnosed by serum beta-hCG.
Both
20 Years and older
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00093236
NIDCR-15345, R01DE015345
Yes
Salomon Amar, DMD, Ph.D., Boston University Medical Campus
Boston University
National Institute of Dental and Craniofacial Research (NIDCR)
Principal Investigator: Salomon Amar, DMD, Ph.D Boston University
Boston University
March 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP